Study identifier:5077US/0049
ClinicalTrials.gov identifier:N/A
EudraCT identifier:N/A
CTIS identifier:N/A
-
Bipolar Disorder
Phase 3
No
SEROQUEL (quetiapine fumarate) Tablets
All
-
Interventional
18 Years - 65 Years
Allocation: None
Endpoint Classification: None
Intervention Model: None
Masking: None
Primary Purpose: Treatment
Verified 01 Nov 2013 by AstraZeneca Pharmaceuticals
AstraZeneca Pharmaceuticals
-
The purpose of this study is to evaluate the efficacy and safety of quetiapine in the treatment of a major depressive episode in patients with bipolar disorder.
Location
Location
Beverly Hills, CA, United States
Location
La Mesa, CA, United States
Location
San Diego, CA, United States
Location
Jacksonville, FL, United States
Location
Orlando, FL, United States
Location
West Palm Beach, FL, United States
Location
Winter Park, FL, United States
Location
Atlanta, GA, United States
Arms | Assigned Interventions |
---|
This information is not intended to replace the informed medical advice or medical treatments of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. If you have questions regarding any information contained in this site, you must consult a suitably qualified healthcare professional. Before prescribing any AstraZeneca products, Healthcare Professionals should view their country specific information.